BioMarker Strategies is an emerging tissue-based cancer diagnostics company that is developing the novel SnapPath™ biomarker testing system to predict and monitor patient response to drug therapy. The company is located at the Johns Hopkins Science + Technology Park in Baltimore, MD. To date, the company has raised more than $4.3 million from qualified private investors and has been awarded over $2M in federal and state grants/contracts. The company was also recently selected as one of the “Top 20 Most Promising Startups” in the United States, out of 1,200 companies considered, by the editors of the Thomson-Reuters Venture Capital Journal.